delavirdine
Trade name: rescriptor
Approved
Apr 4, 1997
Delavirdine is a nonnucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities. Delavirdine does not compete with template:primer or deoxynucleoside triphosphates. HIV-2 RT and human cellular DNA polymerases alfa, gamma, or delta are not inhibited by delavirdine. In addition, HIV-1 group O, a group of highly divergent strains that are uncommon in North America, may not be inhibited by delavirdine. Delavirdine is marketed under the trade name Rescriptor, indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. . — NCATS
Clinical trial activity
23 trials · 8 clinical orgs · 1 marketing orgs
Earliest trial started Mar 1, 1999 (NCT02249130)
Timeline
1990s
- Apr 4, 1997
ViiV Healthcare — Earliest FDA Approval
- Apr 4, 1997
ViiV Healthcare — NDA Organization
- Apr 4, 1997
ViiV Healthcare — NDA Secondary Org
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
Q72547 inhibitor
Approval history
- approvedPriority reviewAcceleratedApr 4, 1997
Chemistry & pharmacology
SMILES
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1- Mol. weight
- 456.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL593 ↗
- WikipediaDelavirdine ↗
- NCATSDOL5F9JD3E ↗
- ChEMBLCHEMBL929 ↗
Also known as
- 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1h-indol-2-yl)carbonyl)piperazine
- 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1h-indol-2-yl)carbonyl)piperazine
- 2-(4-(5-methanesulfonamido-1h-indol-2-ylcarbonyl)-1-piperazinyl)-n-(1-methylethyl)-3-pyridinamine
- 2-(4-(5-methanesulfonamido-1h-indol-2-ylcarbonyl)-1-piperazinyl)-n-(1-methylethyl)-3-pyridinamine
- delavirdin
- delavirdin
- delavirdina
- delavirdina
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine
- delavirdine mesilate
- delavirdine mesylate
- delavirdine mesylate
- delavirdine mesylate
- delavirdine mesylate
- delavirdine mesylate
- delavirdinum
- delavirdinum
- n-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1h-indol-5-yl)methanesulfonamide
- n-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1h-indol-5-yl)methanesulfonamide
- (n-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1h-indol-5-yl] methanesulfonamide)
- (n-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1h-indol-5-yl] methanesulfonamide)
- n-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1h-indol-5-yl}-methanesulfonamide
- n-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1h-indol-5-yl}-methanesulfonamide
- rescriptor
- rescriptor
- rescriptor
- rescriptor
- rescriptor
- u-90152
- u-90152
- u-90152s
- u-90152s
- u-90152t
- u-90152t
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03631732 | Phase 3 | Aug 28, 2018 | Gilead Sciences |
| NCT02858401 | Phase 1 | Jan 29, 2015 | Gilead Sciences |
| NCT00445146 | Phase 2 | Feb 1, 2007 | Gilead Sciences |
| NCT00232908 | Phase 4 | Jun 1, 2004 | Roche |
| NCT00006326 | N/A | Aug 1, 2000 | Agouron |
| NCT00001094 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002123 | Phase 3 | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002124 | Phase 3 | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002178 | Phase 3 | Nov 2, 1999 | Roche |
| NCT00002210 | Phase 2 | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002211 | N/A | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00000803 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002312 | N/A | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002378 | Phase 3 | Nov 2, 1999 | Roche |
| NCT00002400 | N/A | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002401 | N/A | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00002420 | Phase 2 | Nov 2, 1999 | Bristol-Myers Squibb, Pharmacia & Upjohn, Triangle Pharmaceuticals |
| NCT00002236 | N/A | Nov 2, 1999 | Pharmacia & Upjohn |
| NCT00000810 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000882 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharmacia & Upjohn | For profit | 9 | 8 | 3 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 6 | 6 | 3 | 1999 |
| Gilead Sciences | For profit | 3 | 3 | 3 | 2007 |
| Roche | For profit | 3 | 3 | 2 | 1999 |
| Agouron | For profit | 1 | 1 | 1 | 2000 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 1999 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 1999 |
| Triangle Pharmaceuticals | For profit | 1 | 0 | 1 | 1999 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ViiV Healthcare | For profit | NDA | Apr 4, 1997 |
| ViiV Healthcare | For profit | NDA2 | Apr 4, 1997 |